London, UK – 25 May 2018: Ergomed plc, (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce the addition of specialist pharmacoepidemiology services to PrimeVigilance’s offering and the appointment of Dr Michael Forstner as Head of Risk Management and Pharmacoepidemiology. In addition to […]
London, UK – 25 May 2018: Ergomed plc, (LSE: ERGO) (‘Ergomed’ or the ‘Company’), a company focused on providing specialised services to the pharmaceutical industry, is pleased to announce the addition of specialist pharmacoepidemiology services to PrimeVigilance’s offering and the appointment of Dr Michael Forstner as Head of Risk Management and Pharmacoepidemiology.
In addition to the appointment of Dr Forstner, the ongoing contracts of Mesama Consulting, a Swiss-based consultancy founded in 2011 by Professor Jan-Willem van der Velden and most recently owned and managed by Dr Forstner, will be assigned to PrimeVigilance.
Dr Forstner is an expert in pharmacovigilance with significant experience in the planning, development, implementation and evaluation of risk management strategies, including post-authorisation studies, supporting the safe use of medicinal products. His skills will broaden Ergomed’s premium service offering within PrimeVigilance, and build new revenue streams in pharmacoepidemiology and risk minimisation services, meeting high demand for these services.
Stephen Stamp, Chief Executive Officer of Ergomed plc, said: “I am delighted to welcome Michael to Ergomed with his significant experience in PV services, in addition to his unique expertise in pharmacoepidemiology and risk management strategies. His appointment will add value to our PrimeVigilance services as well as providing a bridge between CRO and PV, which fits perfectly in our strategy to leverage our expertise in pharmacovigilance and late phase clinical research, and build a new revenue stream in both our PV and specialist CRO services. We remain focused on growing both of our service offerings organically and through strategic acquisitions.”
Tel: +44 (0) 1483 503 205
Stephen Stamp (Chief Executive Officer)
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Joint Broker)
N+1 Singer (Joint Broker)
Tel: +44 (0) 20 7496 3000
Consilium Strategic Communications – for UK enquiries
Tel: +44 (0) 20 3709 5700
Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Philippa Gardner
MC Services – for Continental European enquiries
Tel: +49 211 5292 5222
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: https://ergomedplc.com.